Stable, concentrated radionuclide complex solutions
The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
1. A pharmaceutical aqueous solution comprising:
(a) a complex comprising
(ai) the radionuclide 177 Lu, and
(aii) a somatostatin receptor binding peptide linked to the chelating agent DOTA; and
(b) at least one stabilizer(s) against radiolytic degradation;
wherein:
the at least one stabilizer(s) against radiolytic degradation is/are present in a total concentration of 0.5 mg/mL to 10.0 mg/mL;
the activity of the pharmaceutical aqueous solution is 7.4 GBq ±10%;
the volume of the pharmaceutical aqueous solution is 10 mL to 50 mL; and
the pharmaceutical aqueous solution comprises less than 1% ethanol.
2. The pharmaceutical aqueous solution of claim 1 , wherein the radiochemical purity of the pharmaceutical aqueous solution as determined by HPLC can be maintained at ≥95% for at least 72 hours when stored at 25° C.
3. The pharmaceutical aqueous solution of claim 1 , wherein the pharmaceutical aqueous solution is a ready-to-use single dose pharmaceutical aqueous solution.
4. The pharmaceutical aqueous solution of claim 1 , wherein the pharmaceutical aqueous solution is provided in numerous dose units.
5. The pharmaceutical aqueous solution of claim 1 , wherein the at least one stabilizer(s) against radiolytic degradation is/are present in a total concentration of 1.0 mg/mL to 5.0 mg/mL.
6. The pharmaceutical aqueous solution of claim 1 , wherein the at least one stabilizer(s) against radiolytic degradation comprises ascorbic acid or a salt thereof.
7. The pharmaceutical aqueous solution of claim 1 , wherein the somatostatin receptor binding peptide and the chelating agent form together a molecule selected from DOTA-OC, DOTA-TOC (edotreotide), DOTA-NOC, DOTA-TATE (oxodotreotide), DOTA-LAN, DOTA-VAP, and Satoreotide tetraxetan.
8. The pharmaceutical aqueous solution of claim 7 , wherein the somatostatin receptor binding peptide and the chelating agent form together DOTA-TATE (oxodotreotide).
9. The pharmaceutical aqueous solution of claim 1 , wherein the pharmaceutical aqueous solution is free of ethanol.
10. The pharmaceutical aqueous solution of claim 1 , further comprising a sequestering agent.
11. The pharmaceutical aqueous solution of claim 10 , wherein the sequestering agent is diethylentriaminepentaacetic acid (DTPA) or a salt thereof.
12. A dose unit container enclosing the pharmaceutical aqueous solution of claim 1 .
13. A lead container enclosing the dose unit container of claim 12 .
14. A dose unit container comprising a dose unit comprising 10 to 50 mL of a pharmaceutical aqueous solution, the pharmaceutical aqueous solution comprising:
(a) a complex comprising
(ai) the radionuclide 177 Lu, and
(aii) a somatostatin receptor binding peptide linked to the chelating agent DOTA; and
(b) at least one stabilizer(s) against radiolytic degradation;
wherein:
the at least one stabilizer(s) against radiolytic degradation is/are present in a total concentration of 0.5 mg/mL to 10.0 mg/mL;
the activity of the pharmaceutical aqueous solution is 7.4 GBq ±10%; and
the pharmaceutical aqueous solution comprises less than 1% ethanol.
15. The dose unit container of claim 14 , wherein the radiochemical purity of the pharmaceutical aqueous solution as determined by HPLC can be maintained at ≥95% for at least 72 hours when stored at 25° C.
16. The dose unit container of claim 14 , wherein the pharmaceutical aqueous solution is a ready-to-use single dose pharmaceutical aqueous solution.
17. The dose unit container of claim 14 , wherein the container comprises a stoppered vial comprising the pharmaceutical aqueous solution.
18. A lead container enclosing the dose unit container of claim 14 .
19. A lead container enclosing the dose unit container of claim 17 .
20. A method of treating a tumor in a patient in need thereof, the method comprising administering to the patient the dose unit in the dose unit container of claim 14 .
21. A method of treating a tumor in a patient in need thereof, the method comprising administering the pharmaceutical aqueous solution of claim 1 to the patient.
22. The method of claim 21 , wherein the administering is by injection or infusion.
23. A method of treating a tumor in a patient in need thereof, the method comprising administering to the patient 10 mL to 50 mL of a pharmaceutical aqueous solution comprising:
(a) a complex comprising
(ai) the radionuclide 177 Lu, and
(aii) a somatostatin receptor binding peptide linked to the chelating agent DOTA; and
(b) at least one stabilizer(s) against radiolytic degradation;
wherein:
the at least one stabilizer(s) against radiolytic degradation is/are present in a total concentration of 0.5 mg/mL to 10.0 mg/mL;
the dose administered to the patient is 7.4 GBq ±10%; and
the pharmaceutical aqueous solution comprises less than 1% ethanol.
24. The method of claim 23 , wherein the radiochemical purity of the pharmaceutical aqueous solution as determined by HPLC can be maintained at ≥95% for at least 72 hours when stored at 25° C.
25. The method of claim 23 , wherein the tumor is a neuroendocrine tumor (NET).
26. The method of claim 23 , wherein the tumor is selected from the group consisting of gastroenteropancreatic neuroendocrine tumor, neuroendocrine carcinoid tumor, neuroendocrine small cell lung cancer, neuroendocrine glioma, neuroendocrine prostate cancer, neuroendocrine meningioma, neuroendocrine neuroblastoma, neuroendocrine paraganglioma, neuroendocrine pheochromocytoma, pulmonary NET, neuroendocrine medullary thyroid cancer, neuroendocrine breast cancer, neuroendocrine head & neck tumor and pancreatic NET, neuroendocrine thymic cancer and lung NET.
27. The method of claim 23 , wherein the administering is by injection or infusion.
28. The method of claim 23 , wherein the pharmaceutical aqueous solution is administered to the patient within a period of about 20 minutes to about 30 minutes.
29. The pharmaceutical aqueous solution of claim 11 , wherein the DTPA or a salt thereof is present in an amount to result in a concentration of 0.01 mg/mL to 0.10 mg/mL.
30. The method of claim 26 , wherein the tumor is a gastroenteropancreatic neuroendocrine tumor.